Search research articles
Contact Us
Filters
Showing results (71-80 of 74) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 74 results.
Annals of Surgical Oncology
|
March 25, 2026
Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial
Yan Yan, Yichao Han, Zhenyi Niu, et al.
Translational Lung Cancer Research
|
June 19, 2025
Impact of coronavirus disease 2019 on surgery in patients with early-stage lung cancer: the COVIDLungSurg prospective cohort study
Zhenyi Niu, Feng Zhu, Yuqin Cao, et al.
Signal Transduction and Targeted Therapy
|
November 27, 2025
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)
Chengqiang Li, Yichao Han, Shengguang Zhao, et al.
Nature Medicine
|
July 2, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Jianjun Qin, Liyan Xue, Anlin Hao, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 74) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 74 results.
Annals of Surgical Oncology
|
March 25, 2026
Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial
Yan Yan, Yichao Han, Zhenyi Niu, et al.
Translational Lung Cancer Research
|
June 19, 2025
Impact of coronavirus disease 2019 on surgery in patients with early-stage lung cancer: the COVIDLungSurg prospective cohort study
Zhenyi Niu, Feng Zhu, Yuqin Cao, et al.
Signal Transduction and Targeted Therapy
|
November 27, 2025
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)
Chengqiang Li, Yichao Han, Shengguang Zhao, et al.
Nature Medicine
|
July 2, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Jianjun Qin, Liyan Xue, Anlin Hao, et al.
Page
of 8